Targeted therapies for bone sarcomas.

Bonekey Rep

INSERM, UMR 957, Faculty of Medicine, University of Nantes , Nantes, France ; Faculté de Médecine, Université de Nantes, Nantes Atlantique Universités, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives , Nantes, France ; University Hospital, Hôtel Dieu , CHU de Nantes, France ; Equipe Labellisée Ligue Nationale Contre le Cancer 2012 , Nantes, France.

Published: July 2013

Bone sarcomas include a very large number of tumour subtypes, which originate form bone and more particularly from mesenchymal stem cell lineage. Osteosarcoma, Ewing's sarcoma and chondrosarcoma, the three main bone sarcoma entities develop in a favourable microenvironment composed by bone cells, blood vessels, immune cells, based on the 'seed and soil theory'. Current therapy associates surgery and chemotherapy, however, bone sarcomas remain diseases with high morbidity and mortality especially in children and adolescents. In the past decade, various new therapeutic approaches emerged and target the tumour niche or/and directly the tumour cells by acting on signalling/metabolic pathways involved in cell proliferation, apoptosis or drug resistance. The present review gives a brief overview from basic to clinical assessment of the main targeted therapies of bone sarcoma cells.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817966PMC
http://dx.doi.org/10.1038/bonekey.2013.112DOI Listing

Publication Analysis

Top Keywords

bone sarcomas
12
targeted therapies
8
therapies bone
8
bone sarcoma
8
bone
7
sarcomas bone
4
sarcomas include
4
include large
4
large number
4
number tumour
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!